Results 241 to 250 of about 2,728,064 (259)

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial. [PDF]

Neurology
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study

European Journal of Neurology, 2021
A rapid response to preventive therapy is of pivotal importance in severely disabled patients with chronic migraine (CM) and diverse preventive treatment failures.
F. Vernieri, C. Altamura, N. Brunelli, C. Costa, C. Aurilia, G. Egeo, L. Fofi, V. Favoni, C. Lovati, D. Bertuzzo, F. D’onofrio, A. Doretti, Paola Di Fiore, C. Finocchi, Francesca Schiano di Cola, A. Ranieri, B. Colombo, Frances A. Bono, M. Albanese, S. Cevoli, P. Barbanti   +20 more
semanticscholar   +1 more source

Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

Headache, 2021
To evaluate the long‐term effectiveness, safety, and tolerability of erenumab in a real‐world migraine population, looking for putative predictors of responsiveness.
P. Barbanti, C. Aurilia, S. Cevoli, G. Egeo, L. Fofi, R. Messina, Antonio Salerno, P. Torelli, M. Albanese, Antonio Carnevale, Frances A. Bono, D. D’Amico, M. Filippi, C. Altamura, F. Vernieri   +14 more
semanticscholar   +1 more source

Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine

Cephalalgia, 2020
Introduction Acute medication overuse is prevalent in patients with migraine. Methods In three phase 3, double-blind, randomized, placebo-controlled studies, patients with episodic migraine (EVOLVE-1 and EVOLVE-2) or chronic migraine (REGAIN) were ...
D. Dodick, E. Doty, S. Aurora, D. Ruff, V. Stauffer, J. Jedynak, Yan Dong, E. Pearlman   +7 more
semanticscholar   +1 more source

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

Cephalalgia, 2020
Background This study reports the long-term safety and efficacy of erenumab in chronic migraine patients. Methods This was a 52-week open-label extension study of a 12-week double-blind treatment phase study.
S. Tepper, M. Ashina, U. Reuter, J. Brandes, D. Doležil, S. Silberstein, P. Winner, Feng Zhang, Sunfa Cheng, D. Mikol   +9 more
semanticscholar   +1 more source

Proposed new diagnostic criteria for chronic migraine

Cephalalgia, 2020
Introduction ICHD-3 criteria for chronic migraine (CM) include a mixture of migraine and tension-type-like headaches and do not account for patients who have a high frequency of migraine but no other headaches.
M. A. Chalmer, T. Hansen, E. Lebedeva, D. Dodick, R. Lipton, J. Olesen   +5 more
semanticscholar   +1 more source

Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies

Cephalalgia, 2020
Background and purpose An estimated 2.5–3.1% of people with episodic migraine develop chronic migraine in a year. Several risk factors are associated with an increased risk for this transformation.
Jingjing Xu, Fanyi Kong, D. Buse
semanticscholar   +1 more source

Cortical morphological changes in chronic migraine in a Taiwanese cohort: Surface- and voxel-based analyses

Cephalalgia, 2020
Background Previous voxel- or surface-based morphometric analysis studies have revealed alterations in cortical structure in patients with chronic migraine, yet with inconsistent results.
K. Lai, D. Niddam, J. Fuh, Wei-Ta Chen, Jaw‐Ching Wu, Shuu-Jiun Wang   +5 more
semanticscholar   +1 more source

Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis

Journal of Pain & Palliative Care Pharmacotherapy, 2020
Erenumab is a monoclonal antibody that mediates calcitonin-gene-related peptide (CGRP), a pro-inflammatory polypeptide implicated in migraine pathology, by targeting its receptor.
M. Armanious, N. Khalil, Yuanyuan Lu, Rebecca Jimenez-Sanders   +3 more
semanticscholar   +1 more source

Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study

Headache, 2020
To assess the effectiveness, safety, and tolerability of erenumab in a real‐life migraine population, while trying to identify responsiveness predictors.
P. Barbanti, C. Aurilia, G. Egeo, L. Fofi, S. Cevoli, B. Colombo, M. Filippi, F. Frediani, Frances A. Bono, L. Grazzi, Antonio Salerno, B. Mercuri, Antonio Carnevale, C. Altamura, F. Vernieri   +14 more
semanticscholar   +1 more source